- Previous Close
33.71 - Open
33.75 - Bid 35.03 x 20000
- Ask 35.44 x 20000
- Day's Range
33.69 - 35.38 - 52 Week Range
27.10 - 38.50 - Volume
185 - Avg. Volume
50 - Market Cap (intraday)
231B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
19.99 - EPS (TTM)
1.77 - Earnings Date Jan 30, 2025
- Forward Dividend & Yield 1.30 (3.85%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
--
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RHO6.F
View MorePerformance Overview: RHO6.F
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHO6.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHO6.F
View MoreValuation Measures
Market Cap
220.82B
Enterprise Value
248.16B
Trailing P/E
19.09
Forward P/E
12.02
PEG Ratio (5yr expected)
1.07
Price/Sales (ttm)
3.35
Price/Book (mrq)
6.96
Enterprise Value/Revenue
3.84
Enterprise Value/EBITDA
13.13
Financial Highlights
Profitability and Income Statement
Profit Margin
17.53%
Return on Assets (ttm)
12.49%
Return on Equity (ttm)
36.36%
Revenue (ttm)
60.58B
Net Income Avi to Common (ttm)
10.62B
Diluted EPS (ttm)
1.77
Balance Sheet and Cash Flow
Total Cash (mrq)
8.81B
Total Debt/Equity (mrq)
110.04%
Levered Free Cash Flow (ttm)
8.13B